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HHV Human Herpesvirus 
HIV Human Immunodeficiency Virus 
HNB Hydroxynaphthol blue 
HNSCC Head and neck squamous cell carcinoma 
HPV Human papillomavirus 
HPV-OSCC HPV associated OSCC 




HPLC High performance liquid chromatography 
H&E Hematoxylin and Eosin 
IARC International Agency for Research on Cancer 
ICD-10 International Classification of Disease (ICD-10) 
ICTV International committee on taxonomy of viruses 
IDT Integrated DNA technologies 
IgG  Immunoglobulin type G 
IHC Immunohistochemistry 
ISH In-situ hybridisation 
ITF Invasive Tumour Front 
L Litre 
LAMP Loop-mediated isothermal amplification 
LB Loop backward primer 
LCR Long control region 
LF Loop forward primer 




MgCl2 Magnesium chloride 




mRNA Messenger ribonucleic acid 
NaCl Sodium chloride 
NBF Neutral buffer formalin 
NASBA Nucleic acid sequence-based amplification 
NCBI National Center for Biotechnology Information 
NCI National Cancer Institute 
ng Nanogram 




NPV Negative predictive value 
OCRCC  Oral Cancer Research & Coordinating Centre 
OD Optical density 
OPMDs Oral potentially malignant disorders 
OPSCC Oropharyngeal squamous cell carcinoma 
OSCC Oral squamous cell carcinoma 
PBS Phosphate buffer saline 
PC Personal computer 
PCR Polymerase chain reaction 
PFU Plaque forming unit 
pH Potential hydrogen 
PPV Positive predictive value 




QC Quality control 
qLAMP Real-time loop mediated isothermal amplification  
qPCR Quantitative polymerase chain reaction 
RCA Rolling circle amplification 
RE Restriction enzyme 
RFLP Restriction-fragment length polymorphism 
RNA Ribonucleic acid 
RPA Recombinase polymerase amplification 
RT-PCR Reverse-transcriptase polymerase chain reaction 
SCC Squamous cell carcinoma 
SD Standard deviation 
SDA Strand displacement amplification 
SEA South East Asia 
SEER 
SNR 
Surveillance, Epidemiology, and End Results 
Signal-to-noise ratio 
SPSS Statistical product and service solutions 
ssDNA Single-stranded deoxyribonucleic acid 
Ta Annealing temperature 
Taq Thermus aquaticus 
TBE Tris-Borate-EDTA 
Tm Melting temperature 
TNM Classification of Malignant Tumours 
TORS Transoral robotic surgery 
Tt Threshold/amplification time 
U Unit 
UK United Kingdom 
UM Universiti Malaya 
URR Upstream regulatory region 
USA United States of America 
USB Universal Serial Bus 
USM Universiti Sains Malaysia 
UV Ultraviolet 
V Volts 
VEGF Vascular endothelial growth factor 
WHO World Health Organization 
X Times or multiplication 




PEMBANGUNAN ASAI AMPLIFIKASI ISOTERMA BERPENGANTARA 
GELUNG MASA-NYATA DAN PCR UNTUK PENGESANAN 
PAPILLOMAVIRUS MANUSIA 16 DALAM  




Penglibatan papillomavirus manusia genotip 16 (HPV-16) dalam 
pembangunan karsinoma mulut sel skuamus (OSCC) telah didokumentasikan dengan 
baik. Pengesanan virus ini adalah penting untuk pengkelasan OSCC positif dan negatif 
kerana ia mempengaruhi prognosis pesakit. Kaedah pengesanan konvensional untuk 
HPV berisiko tinggi bergantung pada penanda surogat pewarnaan p16 
imunohistokimia (p16 IHC) yang mempunyai kelemahan kerana proses yang panjang, 
memerlukan 20-24 jam untuk disiapkan, kadar spesifikasi yang rendah (46% hingga 
78%), interpretasi pewarnaan yang subjektif (berjulat antara 5% hingga 75%), 
memerlukan pakar patologi untuk interpretasi keputusan dan kit yang mahal. 
Sehubungan dengan itu, dalam usaha untuk menambahbaik ujian diagnostik bagi 
pengesanan HPV-berkaitan kanser mulut, kami telah membangunkan asai amplifikasi 
isoterma berpengantara gelung masa-nyata (qLAMP) untuk pengesanan pantas, 
sensitif, spesifik dan kuantitatif untuk pengesanan HPV-16 dalam OSCC. Fasa 
pertama kajian difokuskan pada pembangunan asai qLAMP dan PCR, manakala dalam 
fasa kedua, asai yang telah dibangunkan dinilai dengan menggunakan sampel klinikal 
OSCC (tisu, n = 63; air liur, n = 13; dan darah, n = 59) dan sampel dari subjek yang 
sihat (air liur, n = 50). Pewarnaan rutin hematoxylin dan eosin (H&E) dan p16 IHC 
pada tisu parafin tertanam (FFPE) dijalankan untuk menilai tahap histologi tumor dan 
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menentukan positiviti HPV berisiko tinggi, masing-masing. Nilai Kappa ditentukan di 
antara dua penilai untuk pewarnaan p16. Nilai kepekaan, kekhususan, nilai ramalan 
positif (PPV), nilai ramalan negatif (NPV) dan ketepatan asai qLAMP dinilai dan 
dibandingkan dengan asai PCR dan pewarnaan p16. Dalam kajian ini, asai qLAMP 
yang dibangunkan berjaya mengenalpasti HPV-16 secara spesifik tanpa reaksi silang 
dengan strain HPV yang berlainan, virus respiratori dan bakteria mulut. Amplifikasi 
positif dapat dikesan seawal minit ke 21:18 dan keseluruhan proses boleh disiapkan 
dalam masa satu jam. Nilai LOD bagi asai qLAMP dan PCR adalah 4.68 X 101 dan 
4.68 X 103 salinan dalam setiap tindak balas, masing-masing. Ujian qLAMP yang 
dibangunkan dapat mengesan HPV-16 positif dalam tiga sampel tiga tisu (4.7%) dan 
air liur (23%) pesakit OSCC, manakala PCR dapat mengesan dua (3.17%) HPV-16 
positif dalam sampel tisu dan satu (7.69%) dalam air liur dengan nilai beban virus di 
antara 4.68 X 101 sehingga 4.68 X 104. Pewarnaan p16 menunjukkan tiga positif 
dengan nilai skor H adalah berjulat dari 40 hingga 225% dan tumor ini adalah gred 
terbeza yang baik. Nilai persetujuan Kappa adalah sangat baik (қ = 1.0) bagi dua 
penilai pewarnaan p16. Nilai kepekaan, kekhususan, PPV, NPV dan ketepatan 
pengujian qLAMP terhadap p16 adalah 100%. Nilai kepekaan, kekhususan, PPV, 
NPV dan ketepatan pengujian PCR terhadap p16 adalah 67%%, 100%, 100%, 98% 
and 98%, masing-masing. Kesimpulannya, asai qLAMP yang dibangunkan adalah 
sangat sensitif dan spesifik, dan cepat untuk pengesanan HPV-16 dalam OSCC. Kajian 
ini adalah novel kerana ia adalah yang pertama melaporkan penggunaan kedua-dua 
tisu dan air liur sebagai matriks pengantara untuk mengesan HPV-16 dalam OSCC, 
dan platform pengesanan menggunakan masa-nyata untuk pengesanan nilai beban 
virus jangkitan berbanding dengan kit pengesanan HPV-16 sedia ada.  
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DEVELOPMENT OF REAL-TIME LOOP-MEDIATED ISOTHERMAL 
AMPLIFICATION AND PCR ASSAYS FOR DETECTION OF HUMAN 
PAPILLOMAVIRUS 16 IN ORAL SQUAMOUS CELL CARCINOMA 
ABSTRACT 
 
Human papillomavirus genotype 16 (HPV-16) involvement in the 
development of oral squamous cell carcinoma (OSCC) has been well-documented. Its 
detection is crucial to classify OSCC into positive and negative cases; as this affects 
prognosis. The conventional method of detection for high-risk HPV relies upon p16 
immunohistochemistry (IHC) as a surrogate marker which has drawbacks on its 
lengthiness, low specificity level (46 to 78%), broad range of staining intensity cut-off 
value (range 5 to 75%), requirement of expertise and costly. Thus, in an effort to 
improve the diagnostic test for HPV-related oral cancer, we have developed a real-
time LAMP (qLAMP) assay for rapid, sensitive, specific and quantitative detection of 
HPV-16 in OSCC. The first phase was focused on the development of qLAMP and 
PCR assays, while in the second phase the developed assays were evaluated using 
OSCC clinical samples (tissue, n=63; saliva, n=13; and blood, n=59) and healthy 
(saliva, n=50). The hematoxylin and eosin (H&E) and p16 IHC staining using 
formalin-fixed paraffin embedded (FFPE) tissues was done to evaluate the tumour 
histological grading and determine high-risk HPV positivity, respectively. The Kappa 
value was determined between two raters for p16 staining. The sensitivity, specificity, 
positive predictive value (PPV), negative predictive value (NPV) and accuracy of 
qLAMP were evaluated, in comparison with PCR and p16 IHC. It was found that the 
developed qLAMP assay successfully amplified HPV-16, and no cross-reaction with 
other HPV strains, respiratory viruses and oral bacterial. The positive amplification 
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starts as early as 21:18 minute and the whole process can be completed within one 
hour. The LOD for qLAMP and PCR assays were 4.68 X 101 and 4.68 X 103 copies 
per microliters, respectively. The developed qLAMP assay detected HPV-16 positivity 
in three tissue (4.7%) and saliva (23%) samples from OSCC patients, while the PCR 
assay detected two (3.17%) HPV-16 positives in tissue and one (7.69%) in saliva 
samples, with the HPV-16 viral load ranging from 4.68 X 101 to 4.68 X 104. The 
sensitivity, specificity, PPV, NPV and accuracy of qLAMP assay towards p16 IHC 
were 100%. The sensitivity, specificity, PPV, NPV and accuracy of in-house PCR 
assay were 67%%, 100%, 100%, 98% and 98%, respectively. p16 IHC staining 
showed three positivity of tissues with the H score ranged from 40 to 225% and well-
differentiated grade. Very good agreement (қ = 1.0) was found between two raters for 
evaluation of p16 IHC staining. In conclusion, the developed qLAMP was highly 
sensitive and specific, and rapid for the detection of HPV-16 in OSCC. This study is 
novel as it is the first report describing the use of both tissue and saliva as the sample 
matrix for detection of HPV-16 in OSCC and the detection platform using real-time to 
quantify the viral load of the infection in comparison to the current available HPV-16 





1.1 Background of the study 
Oral cancer is ranked as the 17th among the most common cancer worldwide 
(Globocan, 2018). More than 95% of oral cancers are oral squamous cell carcinomas 
(OSCC). OSCC is defined as a malignant epithelial neoplasm arising from the oral 
cavity and exhibits squamous differentiation characterised by the formation of 
keratin/or the presence of intercellular bridges (Dhanuthai et al., 2018). Worldwide, 
OSCC affects 350,000 people each year (National Cancer Institute, 2018). It occurs 
most often in people over the age of 40 years old and affects more than twice as many 
men as women (Fox et al., 2018). Established risk factors for OSCC include smoking, 
alcohol consumption, betel quid chewing, sunlight, dietary habits, chronic candidal 
infection, genetic predisposition and compromised immune system secondary to organ 
transplant (Lin et al., 2011; Talhout et al., 2011). Recent findings have demonstrated 
the presence of high-risk human papillomavirus in OSCC and their ability to 
immortalise oral keratinocytes by bringing transformation of epithelial cells (Ajila et 
al., 2015; Chen et al., 2016).  Majority of HPV associated OSCC (HPV-OSCC) cases 
are caused by HPV-16 and 18 with the most infected sites are tonsil and base of the 
tongue (Kabeya et al., 2012).To date, there have been more than 200 types of HPV 
subtypes discovered (Pinidis et al., 2016).  The low-risk HPV subtypes (HPV-6, 11, 2, 
43, 44, 54, 61, 70 and 72) are associated with a variety of benign oral papillomatous 
lesions including oral squamous papilloma, oral condyloma accuminatum, oral verruca 
vulgaris, and focal epithelial hyperplasia (Méndez-Martínez et al., 2020). 
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HPV-OSCC cases are rapidly growing and have been reported worldwide (Zhou et al., 
2019). These increasing trends have been observed in many countries, despite the 
decreased in tobacco consumption (Metgud et al., 2012). The reported prevalence of 
HPV-OSCC varies considerably because of the differences in the anatomical site, 
ethnicity, detection methods and geographical setting (Ajila et al., 2015). Worldwide 
prevalence of HPV-OSCC is 3.9% (World Health Organization, 2018) but, a higher 
prevalence rate was observed in many countries, ranged from 60% - 41% (Plummer et 
al., 2016). In Malaysia, there are few studies reported the prevalence of HPV-OSCC 
ranged from 21-51.4% (Heah et al., 2012; Kerishnan et al., 2016; Saini et al., 2011).  
Persistent infection with high-risk HPV is a prerequisite for the development of OSCC. 
Twelve HPV subtypes (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 59) are classified 
by the International Agency for Research on Cancer (IARC) as being carcinogenic to 
humans. Among these, HPV-16 is the predominant type, which accounts for more than 
70% of all cancer diagnosed worldwide (IARC, 2018). Moreover, HPV-16 is the most 
common type found in OSCC, representing >95% of all HPV-positive SCC and also 
the predominant type found in OSCC affecting Malaysian population (Kerishnan et 
al., 2016; Saini et al., 2011). 
Detection of HPV in OSCC have therapeutic and prognostication implications, which 
allows a better estimate for prognosis assessment and potential use in targeted therapy. 
Review of the literature concluded that the presence of HPV in OSCC constitutes a 
positive prognostic marker for the disease. In essence, HPV-positive patients have 
better disease-free survival rate compared to HPV negative group as it has 
demonstrated a higher degree of sensitivity towards radiotherapy and chemotherapy 
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(Ang et al., 2010; Götz et al., 2016). Thus, it is recommended to distinguish HPV-
OSCC from non-HPV-OSCC. Additionally, dose reduction has been suggested for the 
treatment in HPV-OSCC cases. The standard chemo-radiotherapy regimen for the 
treatment of OSCC is considerably an overtreatment for HPV-OSCC and may result 
in toxicity and reduced quality of life (Mirghani and Blanchard, 2017). Thus, the 
discrimination of HPV-OSCC from non-HPV-OSCC is important towards delivering 
accurate treatment for these two groups of patients (Bhargava et al., 2012; Gildener et 
al., 2014). 
Several methods have been described for high-risk HPV detection and genotyping. 
Currently, p16 immunohistochemistry (IHC) is the routine diagnostic test used in the 
clinical setting (Mirghani et al., 2015). Other commonly used methods are in-situ 
hybridization (ISH) and molecular detection assays (Bishop et al., 2012). Detection of 
HPV by PCR can be done using consensus primers, such as PGMY09/PGMY11 and 
GP5+/GP6+ or specific primers targeting on the specific gene (Tawe et al., 2018). 
Various types of isothermal amplification techniques, such as loop-mediated 
isothermal amplification (LAMP), nucleic acid sequence-based amplification 
(NASBA), strand displacement amplification (SDA), helicase-dependent 
amplification (HDA), rolling circle amplification (RCA) and recombinase polymerase 
amplification (RPA) have also been reported for HPV detection (Yan et al., 2014).   
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1.2 Rationale of the study 
Identification of HPV-OSCC is routinely done using p16 IHC, which identify the 
presence of p16 protein, a cell cycle-regulating protein, often overexpressed in 
tumours infected with high-risk HPV. Nevertheless, the protocol is time-consuming; 
requiring 20 – 24 hours to complete all the procedures and a pathologist to validate 
and confirming the test results.  p16 IHC has lack of specificity which were reported 
ranging from 46% to 78%. The result interpretation of staining intensity is 
considerably subjective, where the cut-off value for overexpression of p16 staining 
varies from ⩾5% to ⩾75 (Gronhoj et al., 2014). The p16 staining kit is also expensive 
since it requires an antibody for detection (Klussmann et al., 2003; Westra, 2014). For 
molecular technique method, PCR is favourable due to sensitivity and specificity of 
the results provided. Nevertheless, PCR also demonstrated to have various 
disadvantages. It is time-consuming due to required post-amplification and highly 
sensitive to inhibitor such as haemoglobin, urea, phenol, ethanol, collagen, myoglobin, 
IgG and proteinases (Schrader et al., 2012; Ting-Yin, 2011). PCR also might not be 
suitable in primary clinical settings in developing countries or for field use, because of 
the sophisticated instrumentation required, elaborate and complicated assay 
procedures (Schache et al., 2013).  
 
Due to all the above-mentioned pitfalls, there is a growing demand for the simpler and 
economical molecular test for HPV status determination in OSCC patients. LAMP is 
a versatile isothermal amplification tool that can be applied in various fields. It 
provides a specific, sensitive, rapid and simple method for DNA synthesis. One of the 
most attractive features of this LAMP assay is that the results can be observed and 
determined by dye-mediated visualisation. After a short amplification time, a white 
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precipitate of magnesium pyrophosphate as a by-product is produced and it can be 
observed by the naked eye without any special processing or electrophoresis step 
(Notomi et al., 2000). Moreover, LAMP assay is not relatively affected by inhibitors 
remaining in the DNA extraction step. Relatively simple DNA extraction assays (i.e., 
boiling) can be used for DNA extraction instead of commercial DNA extraction kits 
(Abbasi et al., 2016; Hayashida et al., 2015) can be cost-saving. 
 
Thus, to improve high-risk HPV detection in oral cancer, the present study aimed to 
develop a real-time LAMP (qLAMP) assay for rapid, sensitive, specific and 
quantitative detection of HPV-16 in OSCC. The first phase was focused on the 
development of qLAMP and PCR assays. The second phase was the evaluation of the 
developed assay using OSCC clinical and healthy samples in comparison with 































Figure 1.1 Flowchart of the study 
Primers design for qLAMP & PCR assays 
Primers validation 
Optimisation of qLAMP & PCR assays  
Sensitivity and specificity analysis of qLAMP and PCR assays using 
known DNA templates 
Samples collection & processing 










































healthy subjects  
(Saliva only, n=50)  
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1.3 Objectives of the study 
General objective: 
To develop a real-time loop-mediated isothermal amplification (qLAMP) and 
polymerase chain reaction (PCR) assays for detection of HPV-16 in OSCC. 
 
Specific objectives: 
i. To design and validate specific primers targeting E7 gene of HPV-16 for 
qLAMP and PCR assays. 
ii. To optimize and develop qLAMP and PCR assays for HPV-16 detection in 
clinical samples of OSCC. 
iii. To determine HPV-16 viral load in clinical samples using a constructed 
HPV-16 standard curve 
iv. To evaluate and compare the diagnostic performance of developed HPV-
16 qLAMP assay with p16 IHC using clinical samples of OSCC. 
v. To evaluate and compare the diagnostic performance of the developed 













2.1 Oral squamous cell carcinoma (OSCC) 
Oral squamous cell carcinoma (OSCC) is defined as carcinoma with squamous 
differentiation arising from the mucosal epithelium. Approximately, 90% of the 
OSCCs are in the oral cavity region (World Health Organization, 2018). The term 
“OSCC” is often used interchangeably with oral cancer (Markopoulos, 2012). Based 
on the International Classification of Disease Revision 10, (ICD-10), classification of 
oral cancer is given by codes of C00-C06 for lip and oral cavity, while C09-C10 for 
oropharynx. Oral cavity consists of the front two-thirds of the tongue, the upper and 
lower gums, the lining of the cheeks (buccal mucosa) and lips (labial mucosa), the floor 
of the mouth, ventral surface of the tongue, the ‘bony’ top of the mouth (hard palate) 
and the small area behind the last (wisdom) teeth (retromolar trigone). Oropharynx, 
which located behind the oral cavity includes the back third of the tongue, the soft 
palate, the side and back walls of the throat, and the tonsils  (Chai et al., 2015; Feller 
et al., 2013). 
 
2.1.1 Epidemiology of OSCC 
Cancer incidence and mortality are rapidly growing worldwide. The reasons are 
complex but reflect both ageing and growth of the population, as well as changes in 
the prevalence and distribution of the main risk factors for cancer which are associated 
with socioeconomic development (Bray et al., 2018). Based on the epidemiology data 
extracted from GLOBOCAN database 2018, it was estimated that 18.1 million new 
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cases and 9.6 million cancer deaths occurred worldwide in 2018. Among these, cases 
involving the lip and oral cavity (C00‐C06) accounted for 354 864 (2.20%) of new 
cases and 177 384 (2.01%) of deaths. Meanwhile, cases for oropharynx (C09-C10) 
encountered for 92 887 (0.51%) of new cases and 51 005 (0.53%) of death. To date, 
oral cancer and oropharynx cancer have been ranked as the 17th and 25th worldwide, 
respectively (Globocan, 2018). OSCC is predominantly found among males as 
compared to females where 320 892 new cases per year found in men and 126 859 in 
women. The highest incidence rates were seen in Papua New Guinea (25.0 per 
100,000), followed by Melanesia as a whole (19.0 per 100,000), Maldives (11.0 per 
100,000), Sri Lanka (10.3 per 100,000), Bangladesh (9.4 per 100,000) and India (7.2 
per 100,000) (Bray et al., 2018; Globocan, 2018).  
 
In Malaysia, 667 new oral cancer cases were reported on 2018 and 327 deaths were 
recorded. The 5-year prevalence is 6%, ranking oral cancer as the 19th among 36th 
listed cancers by GLOBOCAN. Although OSCC is predominant among males, in 
Malaysia, the prevalence of OSCC is found higher in females compared to males. A 
study among Malaysian population demonstrated the male-to-female ratio of 0.92:1 
and a similar finding was reported among Thailand population (Khan et al., 2008). As 
Malaysia and Thailand are neighbouring countries, residents are exposed to a similar 
type of environment and share some cultural practices, so both countries elicit a female 
predilection (Dhanuthai et al., 2017). In Malaysia, oral cancer was reported due to 




2.1.2 Risk factors of OSCC 
There are certain stimuli known to induce OSCC either genetically or systematically, 
which can be divided into three broad groups, namely chemical, physical and viral 
infections. Among these three stimuli, chemical carcinogens are the main culprit 
contributed to the problem in which tobacco and alcohol are the most commonly 
abused (Hanahan and Weinberg, 2011).  
 
2.1.2 (a) Tobacco/betel quid 
Tobacco is a leafy plant grown around the world. There are many chemicals found in 
tobacco leaves created by burning (as in cigarettes). Chemical produces by smoking 
such as nitrosamines, polycyclic aromatic hydrocarbons, aldehydes, aromatic amines, 
phenols, nitro compounds, volatile hydrocarbons, including other organic and 
inorganic compounds can cause serious harm to the body (Talhout et al., 2011). 
Smokers have nine times greater risk to develop OSCC compared to non-smoker 
which 80% of the reported OSCC patients are smokers (Gupta and Johnson, 2014). 
Although several tobacco agents play a role in the development of the tumour, the 
potent effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) and N'-
nitrosonornicotine (NNN) are unique. Metabolically activated NNK and NNN induce 
deleterious mutations in oncogenes and tumour suppression genes by forming DNA 
adducts, which could be considered as tumour initiation. Meanwhile, the binding of 
NNK and NNN to the nicotinic acetylcholine receptor promotes tumour growth by 
enhancing and deregulating cell proliferation, survival, migration, and invasion, 
thereby creating a microenvironment for tumour growth. These two unique aspects of 
NNK and NNN synergistically induce cancers in tobacco-exposed individuals (Xue et 
al., 2014). Continuous exposure to tobacco may interrupt genetic metabolism where 
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the cells begin to divide at a higher rate. In unusual patterns, this could change the 
maturation of epithelium cells which either be disturbed or become dysplastic. 
Eventually, the damaged mucosa remains deteriorated (Markopoulos, 2012). Each 
cigarette contains about 10 milligrams of nicotine. Nicotine increases dopamine level, 
a neurotransmitter that enhances pleasurable feeling which can lead to addiction 
(Talhout et al., 2011). However, most of the harmful components are not from the 
nicotine, but from chemicals in burning tobacco (Lin et al., 2011).  
 
Smokeless tobacco is defined as unburned tobacco, also known as chewing tobacco, 
oral tobacco, spit or spitting tobacco, dip, and snuff (Gupta and Johnson, 2014). The 
products contain nicotine and 28 known carcinogens which also contribute to OSCC 
(Khan et al., 2014). The most widely used smokeless tobacco is betel quid named 
“khaini” or “gutka”. It is a combination of powdered tobacco and slaked lime paste, 
sometimes with added areca nut (Guha et al., 2014). Betel quid is one of the four most 
commonly used psychoactive substances worldwide. People usually wrapped in betel 
leaf (derived from the Piper betel vine) with at least one of two basic ingredients: 
chewing tobacco and sliced fresh or dried areca nut (Hernandez et al., 2017). The 
leaves then are smeared with aqueous lime and various additives. Users who chew or 
suck tobacco in their mouth will absorb chemical compounds and nicotine through the 
lining of the mouth (Gupta and Johnson, 2014; Ogbureke and Bingham, 2013). These 
smokeless tobacco has been considered a substitute to smoke tobacco, however, 
previous studies demonstrated that there was similar exposure to the tobacco-specific 
carcinogen nicotine-derived nitrosamine ketone in smokers and smokeless tobacco 




In one meta-analysis study, a significant relationship was found between oral cancer 
and betel quid chewing alone (Lee et al., 2012). Betel quid chewing added with 
tobacco was three to five times more likely to develop oral cancer compared to betel 
quid without tobacco (Guha et al., 2014; Gupta and Johnson, 2014). Exposure-
response analyses showed that the risk of oral cancer increased with increasing daily 
amount and duration (years) of chewing betel quid in India, Taiwan and China. In the 
Indian subcontinent, betel quid associated with oral cavity was 5.38–11.13 (95% CI) 
and in Taiwan was 4.86–24.84 (95% CI) (Bray et al., 2018; Guha et al., 2014).  
 
2.1.2 (b) Alcohol 
According to the International Agency for Research on Cancer (IARC), alcohol has 
been shown consistently associated with increased risk of oral cancer, both 
independently and synergistically with tobacco. Numerous studies have been reviewed 
extensively suggested that alcohol play an important role in the development of OSCC. 
People consuming alcohol 170 g per day was said to have 10 times risk in OSCC 
compared to lighter drinker (IARC, 2014). 
 
One possible mechanism through which alcohol consumption may influence the risk 
of OSCC is via conversion of ethanol to acetaldehyde. Alcohol dehydrogenase 3 
(ADH3) converts ethanol to acetaldehyde, which is a suspected oral carcinogen. The 
ADH3*1 allele is associated with increased conversion of ethanol to acetaldehyde, but 
whether the risk of OSCC is increased among ADH3*1 carrier, or whether the risk of 
OSCC attributable to alcohol consumption is unclear (Ram et al., 2011). One meta-
analysis study found a strong direct trend of increasing risk with increased alcohol 
consumption for oral and pharyngeal cancer where alcohol contributed to the entry of 
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carcinogens into an exposed cell, hence altering the oral mucosa cells (Hashibe et al., 
2007). Carcinogenesis may also relate to nutritional deficiencies associated with 
alcoholism because alcohol leads to impaired absorption of nutrient and vitamin 
(Bagnardi et al., 2014).  
 
Heavy drinking, smoking and their synergistic effects are the major risk factors for 
SCC in Western settings (Lin et al., 2011). However, in lower-income countries, such 
as in parts of Asia and Sub-Saharan Africa, the major risk factors for OSCC have yet 
to be elucidated. Meanwhile, a suspected additional risk factor for OSCC in Southern 
America (i.e., in Uruguay, Brazil, and Argentina) is due to drinking very hot mate 
(Bray et al., 2018). 
 
2.1.2 (c) Nutritional intake 
According to World Health Organization (WHO) reports (2016), 35 – 55% of human 
cancer and approximately 15% of OSCC can be attributed to dietary deficiencies or 
imbalances (Stewart and Kleihues, 2016). The relationship between nutrition and 
OSCC can be approached from two different points of views: (1) the direct effect of 
carcinogens presence in food and food additives (i.e., direct carcinogenesis) and (2) 
in-vivo synthesis of carcinogens caused by changes in metabolism due to altered 
dietary habits (i.e., indirect carcinogenesis) (Taghavi and Yazdi, 2007).  
 
With regards to OSCC, among the dietary factors inhibit cancer growth are fibre, 
antioxidants (β-carotene, tea, fresh fruits, and vegetables) and micronutrients (vitamin 
C, E, and K, zinc, folate). The anti-cancer effects of fresh vegetables and fruits on 
OSCC have been confirmed by some previous studies, which were associated to their 
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contents of carotenoids, vitamin A, vitamin C, folic acid, flavonoids, fibre and other 
antioxidants(Chen et al., 2017; Ogbureke and Bingham, 2013; Taghavi and Yazdi, 
2007).  Additionally, there were also several studies reported a relationship between 
seafood intake, particularly fish and inhibition of oral cancer risk (Chen et al., 2017; 
Toledo et al., 2010; Zheng et al., 2013). Fish and seafood contain n-3 polyunsaturated 
fatty acids, mineral salts and proteins which could inhibit tumour progression through 
their anti-inflammatory effects and inhibition of oxygen free radicals (MacLean et al., 
2006).   
 
Monounsaturated fatty acids like n-9 oleic acid, as the main source of fat, behave as a 
tumour promoter in oral cancer (Zheng et al., 2013). Foods rich in fat content such as 
pork, bacon, pasta, cheese, red meat, fried foods, meat fried, or cooked at high 
temperature or in the microwave were significantly associated with the risk of oral 
cancer (Bovell-Benjamin et al., 2010; Toporcov et al., 2004). Fried foods, meat fried 
or cooked at high temperature or in a microwave can be carcinogen because of the 
production of heterocyclic amines (Taghavi and Yazdi, 2007; Toledo et al., 2010). 
Possible mechanisms through which fatty acids may influence carcinogenesis include 
effects on membrane integrity, increase in lipid peroxidase and impairment of nutrient 
metabolism (Chen et al., 2017). 
 
2.1.2 (d) Viral infections 
Recent findings showed that viral infections are significantly found associated with 
OSCC. Majority of oral viral infection manifesting as oral cancer is caused by Human 
papillomavirus (HPV) and Epstein-Barr virus (EBV; HHV-4) (Gillison et al., 2015; 
Metgud et al., 2012; Speicher et al., 2016). The presence of EBV in squamous cell 
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lesions in the oral cavity was proven by Metgud et al. where 60% of SCC was EBV 
positive by PCR and in-situ hybridisation (ISH) (Metgud et al., 2012). Another study 
reported that EBV infection among oral cancer patients in Taiwan population was 
82.5% by microarray analysis (Yen et al., 2009). HPV, particularly HPV-16 has also 
been established for the development of OSCC especially at the base of the tongue and 
the tonsillar area in the younger individuals (D'Souza et al., 2007; Dhanuthai et al., 
2017). The proportions of HPV-positive OSCC were reported in many countries, 
including South Korea (60%), North America (51%), East Europe (50%), Japan 
(46%), Northwest Europe (42%), Australia (41%), South Europe (24%), China (23%), 
India (22%) and Malaysia (20.4%) (Kerishnan et al., 2016; Plummer et al., 2016).  
 
2.1.2 (e) Other risk factors 
Other minor risk factors could contribute to OSCC.  People with poor oral hygiene or 
dental care may have an increased risk of oral cavity cancer (Oji and Chukwuneke, 
2012). Poor dental health or ongoing irritation from poorly fitting dentures and chronic 
hyperplastic candida infection, especially in people who use alcohol and tobacco 
products may contribute to an increased risk of oral and oropharyngeal cancer (Singhvi 
et al., 2017). Some studies indicated a correlation between oral cancer and bacterial 
load which was associated with poor oral hygiene, chronic periodontitis and poor 
dental status (Ahrens et al., 2014; Fitzpatrick and Katz, 2010). 
 
Excessive and unprotected exposure to the sun is linked with cancer on the lip area. 
Sunlight, through actinic radiation, promotes cancer development along the vermilion 
border of the lip (Wood et al., 2011). Sunlight-induced cancers are much more 
common in fair-skinned individuals exposed to the outdoor life than in individuals 
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with darker pigmentation, where it appears that darker pigment protects against actinic 
radiation damage (Amaro-Ortiz et al., 2014). 
 
People with a weakened immune system may have a higher risk of developing oral 
and oropharyngeal cancer (Coghill et al., 2016). Human immunodeficiency virus 
(HIV) infection and organ transplant patients have a high incidence of developing oral 
cancer as compared to the general population (Junaid, 2015). Among HIV-positive 
immunocompromised individuals, HIV-associated oral malignancies have been 
reported where the disease manifests itself first in the oral cavity region (Bajpai and 
Pazare, 2010). 
 
2.1.3 Pathogenesis of OSCC 
During the tumorigenic process, tumor suppressor genes and oncogenes are involved 
(Jurel et al., 2014). Tumor suppressor genes such as p53, PTEN and BRCA1 are 
responsible to promote tumour development when inactivated, while oncogenes such 
as HER2, EGRF and BRAF inhibitor are responsible to promote tumour development 
when activated (Khor et al., 2013). Tumor suppressor genes can be inactivated through 
either mutation, loss of heterozygosity or deletion, or by epigenetic modifications 
(Schache et al., 2011). On the other hand, oncogenes can be activated through gene 
overexpression caused by gene amplification, increased transcription or changes in 
structure due to mutations that lead to increased transforming activity (Knopf et al., 
2015).  
 
Angiogenesis is an important factor for the cancer cell. It is a growth of new blood 
vessels around the cells, functioning to supply blood to the tumour cells. Through 
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blood, the cells will have enough oxygen and other essential nutrients to grow 
(Wadhwan et al., 2015). Among all types of angiogenic factors, vascular endothelial 
growth factor (VEGF) expression, particularly VEGF-A and VEGF-C have been 
reported in OSCC and are dominantly associated with metastasis (Friedrich et al., 
2010; Kapoor and Deshmukh, 2012). 
 
2.1.4 Clinical features of OSCC 
The aetiology of OSCC is a multifactorial, sequential process that starts from normal 
epithelium to invasive and metastatic cancer (Bagan et al., 2010). Cancer starts from 
potentially malignant lesions, such as oral leukoplakia and erythroplakia, followed by 
progression through mild, moderate, and severe degrees of epithelial dysplasia to 
carcinoma in-situ and finally to invasive SCC (Farah et al., 2014). Erythroplakia is 
identifiable red patches while leukoplakia is white patches, a subtle, painless and 
asymptomatic lesion (Isaäc, 2015). In comparison between these two patches, 
erythroplakia have a higher risk of malignant transformation than leukoplakia (Shukla, 
2014). 
 
Other clinical presentations of oral cancer include non-healing ulcer with induration-
fixed to underlying tissue, exophytic or endophytic growth, persistent, non-healing 
extraction, numbness of socket tongue or other areas of the mouth, swelling at jaw 
causing difficulty in wearing denture and hoarseness of voice (Bagan et al., 2010; 
Prasad et al., 2018; van Zyl and Bunn, 2012). At the late stage of cancer, bleeding, 
loosening of teeth, difficulties in swallowing (dysphagia), painful swallowing 
(odynophagia), speech impairment (dysarthria), loss of weight and development of a 
neck mass can be observed (Heijnen et al., 2016; Son et al., 2015). Neck mass is a sign 
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of lymph node metastasis where usually develops in the ipsilateral (on the same side) 
cervical lymph nodes, and distant metastasis to the lung, though any part of the body 
may be affected (Patil et al., 2013).  
 
2.1.5 Histological grading system of OSCC 
The first grading system was proposed by Broders which classified tumour into four 
different grades according to the degree of differentiation and keratinisation of tumour 
cells (Broaders, 1920). However, OSCC is typically a heterogeneous tumour that 
presents cell populations in different stages of differentiation. Therefore, Jakobsson et 
al. developed a multifactorial grading system that was later modified by Anneroth et 
al.. This system considers keratinisation, nuclear pleomorphism, number of mitoses, 
pattern and stage of invasion and lymphoplasmacytic infiltration within the entire 
thickness of the tumour (Anneroth et al., 1987; Jakobsson et al., 1973). 
 
The grading systems have been continuously revised by experts to determine the most 
efficient method to predict patients’ outcomes. Several years later, Bryne et al. 
introduced the concept where the more invasive area of the tumour, known as the 
invasive tumour front (ITF) would be the most relevant to prognosis. These authors 
proposed a method in which only part of the tumour was analysed using the same 
multifactorial criteria proposed previously (Bryne et al., 1989). In 1992, Bryne et al., 
demonstrated that the reproducibility of the system could be improved by excluding 
the mitotic count from the system while the prognostic value remained highly 
significant (Bryne et al., 1992). The most recent WHO guideline suggested a grading 
system based on the degree of cell differentiation by grouping OSCC into three 
categories: well, moderately and poorly differentiated tumour. This system is typically 
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used in routine diagnosis and research; nevertheless, its prognostic factor is 
controversial in the literature (Wagner et al., 2017). 
 
Figure 2.1 showed the histopathological characterisation of SCC according to the 
degree of differentiation; well-differentiated tumour (grade 1), moderately-
differentiated tumour (grade 2) or poorly-differentiated tumour (grade 3) (Krafts, 
2009). In a well-differentiated tumour, the tumour cells resemble normal epithelial 
cells, arranged in an orderly stratification and heavy keratinisation can be found in 
pearl formations. In a moderately-differentiated tumour, the cells are less stratified, 
less keratinized and the tumour contains prickle cells. In grade 3, the cells are poorly 
differentiated and need further additional IHC cytokeratin staining (Alamgir et al., 




















Figure 2.1 Histopathological characterisation of squamous cell carcinoma 
 according to the degree of differentiation. A) Well-differentiated, B) 
 Moderately-differentiated, C) Poorly-differentiated (adopted from 









2.1.6 Classification and staging of OSCC 
To facilitate treatment planning and predictive outcome, tumour, node, and metastases 
(TNM) staging system is recommended. The TNM system is the most widely used 
system for cancer reporting in most hospitals and medical centres (Paul, 2012). Based 
on the TNM system, T (T; T0-T4) refers to the size and extent of the main tumour, N 
(N; N0-N3) refers to the regional lymph node metastasis and M (M; M0-M1) refers to 
distant metastasis from oral cancer to secondary sites such as lung, vertebra, femur, 
pelvis and liver (de Bree et al., 2000). The stage is strongly correlated to the prognosis 
of the patient and is the main contributor to establishing the proper treatment strategy. 
The individual T, N and M values classify the tumour to either of four stages (stage I-
IV), one where the higher stage is strongly associated with worse prognosis (National 
Cancer Institute, 2015). The staging of the tumour is associated with the timing of the 
diagnosis. The earlier the diagnosis, the lower the tumour stage, and hence, a better 
survival rate (83.7%) is noted compared with a lower survival rate with a late 
diagnosis, leading to a higher stage III-IV (38.5%) (Naseer et al., 2016).  
 
2.1.7 Treatment and Prevention of OSCC 
2.1.7 (a) Treatment 
Generally, treatments for early to moderate stage of OSCC (cancer stage I to III) are 
done by surgical and radiotherapy or in a combination of radiotherapy with 
chemotherapy. However, in Stage IV cancer, multidisciplinary non-surgical 
approaches are used to prolong survival and maintain the quality of life (Choi and 
Myers, 2008). The prognosis of HPV-OSCC patients is better compared to non-HPV-
OSCC since they are more susceptible and respond better to the treatment. When both 
groups exempted for chemotherapy, the rate of successful treated HPV-OSCC was 
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82% compared to only 55% among the non-HPV-OSCC (Gillison et al., 2000; Selcuk, 
2016). In-vitro study using HPV positive cell line with the exposure of radiation 
showed increased in apoptosis and decreased in cell survival (Gupta et al., 2009; Liu 
et al., 2018). Recent studies are focusing on the reduction of toxicity-related treatment 
for OSCC patient that include dose reduction of radiotherapy, usage of cetuximab 
instead of cisplatin for chemoradiation, transoral robotic surgery (TORS) and 
immunotherapeutic strategies (Deschuymer et al., 2018; Kofler et al., 2014; Mirghani 
and Blanchard, 2017). 
 
There is a growing amount of data supporting the hypothesis that HPV-OSCC has a 
better survival rate due to a higher sensitivity to chemotherapy and radiotherapy as 
compared to non-HPV-OSCC. Studies showed that the gene expression levels are 
significantly different (347 differentially expressed genes) in HPV-positive versus 
HPV-negative cancers. Differences are particularly among the genes involved in DNA 
regulation and repair, cell cycle regulation, and chemotherapy/radiotherapy-
sensitivity. These differences allow for increased sensitivity to radiation in HPV-
positive cells, hence lead to an improved response to radiation therapy (Liu et al., 
2018; Zhang et al., 2014). 
 
In radiotherapy, the standard dosage ranges from 60-70 gray (Gy) of ionising radiation 
and the reduction in radiation dosage results in less toxicity. In HPV-OSCC, the use 
of 54 Gy has successfully treated the patient. Apart from that, the reduction also 
decreases the cost of the treatment (Buckwalter et al., 2007). For chemotherapy, the 
best agent for this strategy is by using cisplatin. It is the gold standard agent for head 
and neck squamous cell carcinoma (HNSCC) although severe complications are noted 
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on renal, hematologic, neurologic and gastrointestinal toxicities. Hence, for HNSCC, 
a less toxic agent such as cetuximab is used to replace cisplatin for toxicity reduction. 
This showed a promising result where cetuximab plus radiation was used in treating 
HNSCC patients (Kabolizadeh et al., 2012). Moreover, analysis of the 5-year study 
suggested that cetuximab may be useful in HPV-positive patients (Bonner et al., 2006). 
Besides, Phase I clinical trial at the University of Pittsburgh (UPCI 12-084) used the 
combination of ipilimumab (the targeted drug, monoclonal antibody specific to CTLA-
4) plus cetuximab with radiation. Immunologic strategies are among the ongoing 
studies for HPV-OSCC and HPV+ cervical cancer, which involve immunomodulators 
(toll-like receptors), cytokines (IL-2, IL-12, GM-CSF and IFN-alpha), non-viral HPV 
peptide and protein vaccines, DNA vaccines, tumour cellular vaccine, dendritic cell 
vaccines, bacterial vectors, T cell therapy and targeted immunotherapy by a live viral 
vector (Gildener et al., 2014). 
 
2.1.7 (b) Prevention 
Among the prevention strategies is the development of vaccines against HPV. Since 
2006, three vaccines have been approved by the Food and Drug Association (FDA, 
USA) namely Gardasil, Gardasil9 and Cervarix. Gardasil is a quadrivalent vaccine 
used to immunise against HPV-16, 18, 6,11, while Cervarix is a bivalent vaccine for 
HPV-16, 18. Gardasil9 is the latest vaccine approved in 2014 for immunisation against 
HPV 6, 11, 16, 18, 31, 33, 45, 52, and 58 (Satterwhite et al., 2013). All these three 
vaccines have one thing in common, they protect against HPV-16 and 18. These type 
of HPV cause about 70% of cervical cancers and the majority of other HPV-
attributable cancers (Ferlay et al., 2018). These prophylactic HPV vaccines are 90% 
to 100% effective in preventing HPV infections and associated anogenital 
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precancerous lesions (Barr et al., 2008, FDA, 2014). However, these vaccines 
efficacies against oral HPV infection and related diseases is unknown.  
 
WHO recommends the young teenagers (at ages 12) to receive HPV vaccination before 
any sexual activity for preventing cervical cancers (Markowitz et al., 2009). Three 
intramuscular doses in 6 months for men and women are recommended. The USA was 
the first country started the vaccination programme in 2006 for their 12-17 school girls, 
followed by Australia in 2007, United Kingdom in 2008 and Sweden in 2010 (Chandra 
et al., 2011). Malaysia started the vaccination program in 2010. These HPV vaccines 
are meant for prevention of cervical cancer with the prevention rates up to 70% (Ezat 
et al., 2013).  
 
A recent report (June 2017) from the National Cancer Institute (NCI) showed that HPV 
vaccination may decrease the oral HPV infection. When the USA started the first 
vaccination program in 2006, 2600 people were selected to form a study on oral cancer 
with HPV association. The results showed that the prevalence of oral infections with 
HPV was 1.61% in unvaccinated young adults versus 0.11% in vaccinated young 
adults; an 88% reduction in HPV prevalence with vaccination (Chaturvedi et al., 
2018). 
 
Besides vaccination programme, prevention by education and social awareness also 
play an important role. As HPV-OSCC is a sexually transmitted disease, the protection 
methods like condoms and barrier protections during the sexual activity must be used. 
Social awareness and education about the role of the HPV in the development of OSCC 
and the protection methods must be achieved (CDC, 2016).  
